Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cystic fibrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    139 result(s) found for: cystic fibrosis. Displaying page 5 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2011-005790-23 Sponsor Protocol Number: N/A Start Date*: 2012-07-17
    Sponsor Name:Birmingham Children's Hospital NHS Foundation Trust
    Full Title: Comparison of adrenal recovery following short and long-term glucocorticoid therapy.
    Medical condition: Adrenal recovery following long and short term steroid treatment.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10066550 Chronic arthritis LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000842 Acute lymphatic leukaemia LLT
    14.1 10019805 - Hepatobiliary disorders 10008953 Chronic liver disease LLT
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001255-36 Sponsor Protocol Number: GS-US-205-0162 Start Date*: 2012-01-16
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients with Cyst...
    Medical condition: Cystic fibrosis and new onset lower respiratory tract culture positive for Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10070608 Infective pulmonary exacerbation of cystic fibrosis PT
    14.1 10021881 - Infections and infestations 10068288 Cystic fibrosis pulmonary exacerbation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Ongoing) AT (Completed) ES (Completed) NL (Completed) IE (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002579-16 Sponsor Protocol Number: CF001 Start Date*: 2018-08-26
    Sponsor Name:Karolinska University Hospital, Stockholm CF center
    Full Title: Evaluation of the possible use of analysis of posaconazole in exhaled breath as a surrogate marker for the lung to monitor adequate dosages of posaconazole in CF patients treated for Aspergillus sp...
    Medical condition: Cystic Fibrosis (CF) is the most common life–limiting autosomal recessive disease among people of European heritage. The condition is a result of a mutation in the cystic fibrosis transmembrane con...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10074549 Cystic fibrosis respiratory infection suppression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001888-21 Sponsor Protocol Number: DPM-CF-203 Start Date*: 2004-12-03
    Sponsor Name:Pharmaxis Ltd
    Full Title: A cross-over comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis
    Medical condition: Cystic fibrosis (CF)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003052-36 Sponsor Protocol Number: 19067 Start Date*: 2020-01-06
    Sponsor Name:The University of Nottingham
    Full Title: Triple Modality Functional Magnetic Resonance Lung Imaging in Cystic Fibrosis and Non-CF Bronchiectasis
    Medical condition: Cystic fibrosis (CF) Non-CF Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-001214-24 Sponsor Protocol Number: PTI-428-01 Start Date*: 2017-07-27
    Sponsor Name:Proteostasis Therapeutics
    Full Title: A Phase I/II Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects with Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003831-31 Sponsor Protocol Number: MS1819/18/02 Start Date*: 2019-03-28
    Sponsor Name:AzurRx
    Full Title: A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe...
    Medical condition: Exocrine Pancreatic Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10033628 Pancreatic insufficiency LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004344-30 Sponsor Protocol Number: Moli1901-010A Start Date*: 2005-10-31
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease
    Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004761-33 Sponsor Protocol Number: CRO1881 Start Date*: 2012-03-08
    Sponsor Name:Imperial College
    Full Title: A randomised double-blind placebo-controlled Phase 2B clinical trial of repeated application of gene therapy in patients with cystic fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002673-13 Sponsor Protocol Number: APA-IIb Start Date*: Information not available in EudraCT
    Sponsor Name:PSKS
    Full Title: Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo
    Medical condition: Deficiency of the Cftr-molecule results in accumulation of ceramide in respiratory epithelial cells. Ceramide triggers a pro-inflammatory and -apoptotic status in cystic fibrosis patients. Amitript...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000378-30 Sponsor Protocol Number: SMR-3372 Start Date*: 2020-03-04
    Sponsor Name:AlgiPharma AS
    Full Title: A randomised, double-blind, dose finding study of inhaled alginate oligosaccharide (OligoG) vs placebo in patients with Cystic Fibrosis (CF).
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) IE (Completed) AT (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023529-39 Sponsor Protocol Number: RHM CHI 0548 Start Date*: 2011-02-18
    Sponsor Name:Southampton University Hopsitals NHS Trust
    Full Title: Reducing antibiotic tolerance using low dose nitric oxide in cystic fibrosis – a phase 2 pilot study
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000673-37 Sponsor Protocol Number: VX12-770-113 Start Date*: 2017-03-27
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis, Residual CFTR Function, and FEV1 ≥40% Predicted
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003970-28 Sponsor Protocol Number: VX18-561-101 Start Date*: 2019-06-18
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003761-99 Sponsor Protocol Number: VX16-809-121 Start Date*: 2018-06-27
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: An Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, Open label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjec...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003774-27 Sponsor Protocol Number: BC-180-12 Start Date*: 2014-01-20
    Sponsor Name:AlgiPharma AS
    Full Title: An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis pati...
    Medical condition: Cystic fibrosis (CF) is an autosomal, recessive inheritable disease caused by a homozygote defect at the long arm of Chromosome 7. This mutation causes absence or defect of the cystic fibrosis tran...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001317-28 Sponsor Protocol Number: ABBA-2 Start Date*: 2015-07-30
    Sponsor Name:UMC Utrecht
    Full Title: A B2-agonist as a CFTR activator in CF - Part 2
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000164-17 Sponsor Protocol Number: tobra nasal CF pilot Start Date*: 2008-08-13
    Sponsor Name:University of Jena
    Full Title: Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich. Nasal inhalation of tobramycin by the Pari ...
    Medical condition: subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000311-98 Sponsor Protocol Number: P2005V3 Start Date*: 2005-11-09
    Sponsor Name:University of Nottingham
    Full Title: A randomised controlled trial (pilot study) of the use of macerated garlic oil in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa
    Medical condition: Chronic pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002259-33 Sponsor Protocol Number: APA- II Start Date*: 2006-10-10
    Sponsor Name:Paediatrisches Sekretariat fuer Klinische Studien
    Full Title: Protocol for a Phase II-study Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - a randomised, double-blinded, placebo-controlled, cross over study -
    Medical condition: CF-patients develop a chronic pulmonary infection with Pseudomonas aeruginosa (P. aeruginosa). At present it is unknown why CF-patients are highly sensitive to P. aeruginosa infections and, most im...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 08:05:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA